anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A spinal cord injury is a life-changing experience that results in functional limitations and an increased risk of secondary health conditions. People with spinal cord injury identify pain as the most devastating health problem following their injury that not only affects their social life but their mental well-being as well. This study is aimed at exploring the lived experience of living with pain by community-dwelling manual wheelchair users with spinal cord injuries. An explorative qualitative design was used to explore their experiences. In-depth interviews were recorded and transcribed, and the data were analysed using inductive thematic content analysis in the MAXQDA v2020. Fifteen manual wheelchair users with paraplegia participated in this study, and four themes were identified from their experience of living with pain: pain constantly lurks, pain is worse than the direct consequences of the SCI, pain is restrictive, and life continues despite the pain. Categories and subcategories included the participants being one with the pain; pain interfering with sleep; feelings of anger, isolation, and suicidal ideation; and uncertainties about what the future holds living with pain. Living with pain after SCI is a challenging feat, and effective management of pain is necessary to improve not only functioning and mobility but also mental health and life satisfaction.
Systems and methods for providing health monitoring and emergency response services are provided. Each element of the plurality of data elements is obtained from a health monitoring device connected to a corresponding subject of the plurality of subjects. An alarm is triggered by analysis of the data element or manually by the subject or a support loop of the subject. A communication channel is opened between the subject and a member of the support loop. The subject or one or more members of the support loop of the subject verify or reject the alert. The alert is sent to a remote monitoring alarm center and emergency responders are scheduled.
<P>PROBLEM TO BE SOLVED: To provide a bleaching agent and a bleaching cosmetic containing an extract from at least one or more species of plants selected from among Schizandra chinensis Baill., Schizandra repanda (Sieb. et Zucc.) Radlk. and Kadsura japonica Dunal. or Kadsura longipendunculata Finet. et Gagnepen or Kadsura peltigera Rehd.  <P>SOLUTION: The bleaching agent and bleaching cosmetic have inhibitory actions on melanin formation and stability with time of the actions, excretion promoting actions on melanin and excellent bleaching effects and effectively inhibit and ameliorate pigmentation of skin such as dermal stains, ephelides, dullness or skin blackening caused by ultraviolet exposure. The bleaching agent and bleaching cosmetic are extremely highly safe even for human bodies and can be used over a wide range in the fields of medicines, quasi-drugs and cosmetics.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Intervention will consist of 6 series with 3 minutes rest period between the series. The series will consist of burpees, skipping, 1 legged squats, leg levers, and push-ups. the exercise volume will be increased progressively over 8 weeks.
Drug-induced immune thrombocytopenia (DITP) has been reported with ethosuximide. In the reported cases, the onset of symptoms occurred 1 to 3 weeks after initiation of ethosuximide; one patient had recurrence of symptoms within 1 day of a subsequent re-challenge with the drug. In those cases in which the platelet count was specified, the nadir was 2,000 and 3,000/mm3. When DITP is suspected, discontinue ethosuximide, monitor serial platelet counts, and treat as appropriate. If possible, assess the presence of drug-dependent antiplatelet antibodies. Avoid future use of ethosuximide in patients with history of ethosuximide induced DITP.
This study is a single-site phase II, double-blind, placebo-controlled study of Nantheia ATL5 for symptoms of Post-Traumatic Stress Disorder (PTSD) in adults. Subjects will meet criteria for PTSD using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) of ≥ 27. Suicidality is assessed using the Columbia Suicide Severity Rating Scale-Revised (CSSRS-R) at all study visits. Baseline psychopharmacotherapy and/or psychotherapy must be stable (unchanged) for 4 weeks prior to enrollment, and should remain unchanged during study treatment. Effects of Nantheia ATL5 on self-reported quality of life (overall and health-related); functional status measurements of personal and driving (optional) mobility and risk, and sleep dysfunction; neurobiological biomarkers of threat response (optional functional magnetic resonance imaging: fMRI), and serum inflammatory biomarkers (CRP) implicated in PTSD pathophysiology will be assessed. Efficacy and tolerability will be assessed throughout intervention. Serum pregnancy (for subjects of child bearing potential), urine drug screening, CBC, and Comprehensive Metabolic Panel are completed at every on-site visit. Optional consent will be sought from all PTSD and healthy population subjects who agree to complete the fMRI procedures, the driving measures, and providing an additional sample of blood to store for future unspecified research. Baseline characteristics of subjects with PTSD will be evaluated overall and relative to subjects without PTSD (healthy population) during a 3-week baseline period prior to randomization (Nantheia ATL5 or placebo \[PBO\]). Healthy population subjects will complete the study at end of baseline and subjects with PTSD will be randomized 1:1 to Nantheia ATL5 or placebo (PBO). Study drug dose is initiated at 400mg BID and maintained for 8 weeks. Study drug is then withdrawn, and one week later safety measures including laboratory testing, assessment of AE's and CSSRS-R are repeated.
Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and tolerance are not unusual during chronic opioid therapy.

The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

In general, opioids should not be abruptly discontinued. [See DOSAGE AND ADMINISTRATION (2.5)]
Disclosed are methods of forming grafts (e.g., autologous vascular grafts, biliary conduits, ureter conduits, etc.) for implantation into subjects in need thereof. The methods employ an electrospun scaffold formed from nanofibers that comprise a blend of a biodegradable synthetic polymer and a biopolymer. Extracellular matrix-producing cells (e.g., fibroblasts) can then be cultured on the electrospun scaffold in a bioreactor to form a cellular, tubular structure. The tubular structure can then be decellularized, and endothelial cells (e.g., endothelial cells obtained from the subject) can be cultured on the resulting decellularized scaffold to form a graft (e.g., autologous vascular grafts) for implantation into a subject. Because decellularized scaffolds can be prepared in advance, the methods described herein can be used to prepare autologous grafts for implantation in a subject in a relatively short, clinically relevant timeframe (e.g., from one week to one month).
Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
The present invention discloses a Chinese yam preserving agent which relates to the field of a storage and refreshing agent for plants. The Chinese yam preserving agent provided by the present invention is basically composed of the following materials by weight portion: 10 to 15 portions of chinaberry seed, 20 to 40 portions of phellodendron bark, 25 to 50 portions of ash bark, 35 to 40 portions of pulsatilla, 4 portions of alum, 6 portions of cnidium fruit and 2 portions of honeysuckle flower. The Chinese yam preserving agent provided by the present invention obviously lowers the rotting rate of Chinese yam tubers, the reduction rate of the rotting rate is more than 70%, and the storage time of Chinese yam can also be prolonged by 1 to 2 months. The Chinese yam preserving agent is a pure Chinese medicine preparation without pollution to the Chinese yam. The Chinese yam preserving agent of the present invention especially aims at pathogenic microbes causing the Chinese yam to decay in the storage of the Chinese yam, and can effectively overcome the problem of tuber decomposition in the storage and refreshing process of Chinese yam products. Consumers can enjoy high-grade Chinese yam products by using the Chinese yam preserving agent in spring and summer, and the present invention can ensure that the producer and the seller of the Chinese yam can obtain high economic benefit, so the present invention has wide application prospects.
20 endurance trained men and/or women will be recruited. A screening will be done before starting with the test protocol on the treadmill to ensure the suitability of the participants. The test protocol includes two parts. The first part is a maximal ramp test (+0.6km/h each minute until exhaustion). The second part includes a step test with 6 sub maximal stages - each lasting 5 minutes - at 50%, 55%, 60%, 70%, 75% and 80% of the maximal velocity achieved in the first part. There will be a short break between the ramp and the step test. The stationary and the mobile system are tested on 2 separate days with a break of 1-3 days in between. On the second day, procedure will be exactly the same for the participants.
The invention relates to ruditapes philippinarum oligopeptide, the amino acid sequence of which is Asp-Trp-Pro-His. The invention discloses a preparation method of the oligopeptide. According to the preparation method, a target oligopeptide enzymatic hydrolysate is obtained through enzymatic hydrolysis of trypsin; and through ultrafiltration, anion exchange and reversed-phase high-performance liquid chromatography, separation and purification are further carried out to obtain the target oligopeptide. Meanwhile, the invention also discloses an application of the oligopeptide in resisting prostate cancer. Specifically, the oligopeptide can effectively inhibit cell growth of prostate cancer PC-3 and DU-145 cultured in vitro, induce apoptosis and change cell cycle. In comparison with the prior art, the preparation method of the ruditapes philippinarum oligopeptide has advantages of simple technological process, few impurity and high efficiency. Meanwhile, based on the prior art, the invention discloses effectiveness of the oligopeptide in resisting prostate cancer.
Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
In this study, we developed a machine learning model for automated seizure detection using system identification techniques on EEG recordings. System identification builds mathematical models from a time series signal and uses a small number of parameters to represent the entirety of time domain signal epochs. Such parameters were used as features for the classifiers in our study. We analyzed 69 seizure and 55 non-seizure recordings and an additional 10 continuous recordings from Thomas Jefferson University Hospital, alongside a larger dataset from the CHB-MIT database. By dividing EEGs into epochs (1 s, 2 s, 5 s, and 10 s) and employing fifth-order state-space dynamic systems for feature extraction, we tested various classifiers, with the decision tree and 1 s epochs achieving the highest performance: 96.0% accuracy, 92.7% sensitivity, and 97.6% specificity based on the Jefferson dataset. Moreover, as the epoch length increased, the accuracy dropped to 94.9%, with a decrease in sensitivity to 91.5% and specificity to 96.7%. Accuracy for the CHB-MIT dataset was 94.1%, with 87.6% sensitivity and 97.5% specificity. The subject-specific cases showed improved results, with an average of 98.3% accuracy, 97.4% sensitivity, and 98.4% specificity. The average false detection rate per hour was 0.5 ± 0.28 in the 10 continuous EEG recordings. This study suggests that using a system identification technique, specifically, state-space modeling, combined with machine learning classifiers, such as decision trees, is an effective and efficient approach to automated seizure detection.
Mechanisms are provided for training and operating a Question and Answer (QA) system pipeline. A corpus of information is received which comprises historical data to which one or more filter criteria are applied to extract filtered historical data relevant to a training objective for training the QA system pipeline. Attribute data, action data, and temporal characteristic data are captured from the filtered historical data. An answer key entry is automatically generated in an automatically generated training answer key data structure based on the attribute data, action data, and temporal characteristic data. The correct answer associated with the answer key entry is an action specified by the action data. The temporal characteristic data provides a historical context for the answer key entry. The QA system pipeline is trained using the automatically generated training answer key data structure.
AIMS: We aimed to assess the relationships between lower urinary tract symptoms (LUTS) and various parameters including diabetes complications in patients with type 2 diabetes.
METHODS: In this single-center cross-sectional study, we enrolled 404 patients hospitalized for diabetes. We ultimately analyzed data from 160 patients. To evaluate LUTS, the International Prostate Symptom Score and overactive bladder symptom score were used. The identified relationships were then analyzed considering parameters such as age, sex, body mass index (BMI), HbA1c, creatinine, and urinary albumin excretion.
RESULTS: The prevalences of overactive bladder (OAB), storage symptoms and voiding symptoms were 21.9%, 63.8%, and 39.4%, respectively. In multivariate logistic regression analysis, the coefficient of variation of the R-R interval, indicating autonomic neuropathy, correlated negatively with OAB, while BMI and duration of diabetes correlated positively with storage symptoms. A history of cerebrovascular disease correlated significantly with voiding symptoms in multivariate logistic analysis.
CONCLUSIONS: Our analysis of diabetic patients with LUTS revealed differences in the characteristics of storage and voiding symptoms. These findings provide evidence that the features of LUTS associated with diabetes may have different pathogenic origins. J. Med. Invest. 71 : 237-245, August, 2024.
Formulation for the treatment or alleviation of cancer contains an esterified glycyrrhetinic acid of formula (I) and/or one of its pharmaceutically acceptable salts, together with a pharmaceutical diluent or carrier: In (I), R is an aliphatic or cycloaliphatic gp., which can contain >=1 COOH groups. In addn. to their known uses for the treatment of inflammations and ulcerative diseases, (I) can be used to inhibit neoplastic growth and are cytostatic agents. (I) do not give rise to undesired side effects such as disorders of the gastro-intestinal tract, stomatitis, vomiting, skin disorders, alopecia, etc., which are normally caused by other neoplastic agents. In addn., some (I) are used to treat gastro-intestinal disorders. (I) lengthen the life of cancer patients sometimes by several months and causes regression of some of the side effects of cancer such as anorexia and dyspepsia.
A medical condition quantification and dysfunction reduction therapy evaluation process enables a health care service provider to monitor the improvement of a patient's condition, as well as the efficiency of the rehabilitation process employed to achieve a patient improvement objective. Based upon initial patient examination data (200), one or more sets of parameters associated with respective body regions, for which dysfunction reducing therapy is to be carried out, are provided. For each parameter, a data value is generated. The magnitude of the data value is based upon the condition of the body region associated with the parameter. All of the data values of the parameters of a body region are combined (206), to quantify the overall condition or dysfunction of the body region. Periodically, during the course of the patient therapy program, the physical condition of the body region being treated is re-examined (203, 205).
The present invention is directed to a method, i.e. an immunoassay, for determining the presence and/or the amount of anti-zika virus antibodies, i.e. zika virus-specific antibodies in a sample. Therefore, the present invention is directed to a microsphere complex comprising a microsphere coupled to a zika virus like particle, as well as to a kit comprising said microsphere complex and an amount of reporter antibody that binds to the zika virus like particle. The present invention further relates to a method for determining an antibody correlate of protection against zika virus infection for a zika virus vaccine. Moreover, the present invention is directed to a method for diagnosing the protection of a human or non-human subject against a zika virus infection.
PURPOSE: To compare differences in euploidy rates for blastocysts in preimplantation genetic testing for aneuploidy (PGT-A) cycles after gonadotropin-releasing hormone agonist (GnRH-a) long and short protocols, GnRH-antagonist (GnRH-ant) protocol, progestin-primed ovarian stimulation and mild stimulation protocols, and other ovary stimulation protocols.
METHODS: This was a retrospective cohort study from the Assisted Reproductive Medicine Department of Shanghai First Maternity and Infant Hospital. A total of 1657 PGT-A cycles with intracytoplasmic sperm injection after different controlled ovary hyperstimulation protocols were analyzed, and a total of 3154 embryos were biopsied. Differences in euploidy rate per embryo biopsied, embryo euploidy rate per oocyte retrieved and cycle cancellation rate were compared.
RESULTS: For the PGT-A cycles, the euploidy rate per embryo biopsied was lower in the GnRH-ant protocol than in the GnRH-a long protocol (53.26 vs. 58.68%, respectively). Multiple linear regression showed that the GnRH-ant protocol was associated with a lower euploidy rate per embryo biopsied (β =  -0.079, p = 0.011). The euploidy rate per embryo biopsied was not affected by total gonadotropin dosage, duration of stimulation and number of oocytes retrieved. The embryo euploidy rate per oocyte retrieved was similar in all protocols and was negatively correlated with the total number of oocytes retrieved (β =  -0.003, p = 0.003).
CONCLUSION: Compared with the GnRH-a long protocol, the GnRH-ant protocol was associated with a lower euploidy rate per embryo biopsied. The total gonadotropin dosage, duration of stimulation and number of oocytes retrieved did not appear to significantly influence euploidy rates.
ETHNOPHARMACOLOGICAL RELEVANCE: Qingda granule (QDG) is effective for treating hypertension and neuronal damage after cerebral ischemia/reperfusion. However, the anti-neuroinflammatory effect of QDG on injury due to cerebral ischemia/reperfusion is unclear.
AIM OF THE STUDY: The objective was to evaluate the effectiveness and action of QDG in treating neuroinflammation resulting from cerebral ischemia/reperfusion-induced injury.
MATERIALS AND METHODS: Network pharmacology was used to predict targets and pathways of QDG. An in vivo rat model of middle cerebral artery occlusion/reperfusion (MCAO/R) as well as an in vitro model of LPS-stimulated BV-2 cells were established. Magnetic resonance imaging (MRI) was used to quantify the area of cerebral infarction, with morphological changes in the brain being assessed by histology. Immunohistochemistry (IHC) was used to assess levels of the microglial marker IBA-1 in brain tissue. Bioplex analysis was used to measure TNF-α, IL-1β, IL-6, and MCP-1 in sera and in BV-2 cell culture supernatants. Simultaneously, mRNA levels of these factors were examined using RT-qPCR analysis. Proteins of the TLR4/NF-κB/NLRP3 axis were examined using IHC in vivo and Western blot in vitro, respectively. While NF-κB translocation was assessed using immunofluorescence.
RESULTS: The core targets of QDG included TNF, NF-κB1, MAPK1, MAPK3, JUN, and TLR4. QDG suppressed inflammation via modulation of TLR4/NF-κB signaling. In addition, our in vivo experiments using MCAO/R rats demonstrated the therapeutic effect of QDG in reducing brain tissue infarction, improving neurological function, and ameliorating cerebral histopathological damage. Furthermore, QDG reduced the levels of TNF-α, IL-1β, IL-6, and MCP-1 in both sera from MCAO/R rats and supernatants from LPS-induced BV-2 cells, along with a reduction in the expression of the microglia biomarker IBA-1, as well as that of TLR4, MyD88, p-IKK, p-IκBα, p-P65, and NLRP3 in MCAO/R rats. In LPS-treated BV-2 cells, QDG downregulated the expression of proinflammatory factors and TLR4/NF-κB/NLRP3 signaling-related proteins. Additionally, QDG reduced translocation of NF-κB to the nucleus in both brains of MCAO/R rats and LPS-induced BV-2 cells. Moreover, the combined treatment of the TLR4 inhibitor TAK242 and QDG significantly reduced the levels of p-P65, NLRP3, and IL-6.
CONCLUSIONS: QDG significantly suppressed neuroinflammation by inhibiting the TLR4/NF-κB/NLRP3 axis in microglia. This suggests potential for QDG in treating ischemia stroke.
Micronutrients (including vitamins, minerals and certain polyunsaturated fatty acids) are required by the brain for normal functioning and, with few exceptions, can only be obtained through dietary sources. Research into degenerative diseases of aging have linked mitochondrial aging and DNA damage caused by micronutrient deficiency to greater incidence of cognitive decline and stroke, among other diseases, in the general population, particularly in those consuming food rich in fats and carbohydrates but poor in micronutrient content. Other research focusing on cognition, behaviour and mood state has associated micronutrient deficiencies with a wide range of neurological conditions including Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, autism spectrum disorders, depression, fatigue and schizophrenia. There have however been very few studies using micronutrient interventions in post-acute human TBI. In a study with thirty retired American Football players an intervention including supplementation with a broad-spectrum multivitamin, omega-3 fish oils and a number of other substances resulted in significant percentile score improvements in almost half of the participants (n=100) across a broad range of cognitive measures. Findings demonstrated that micronutrient intervention can result in significant measurable improvements in those with TBI many years following the initial insult. A normative study will be conducted with three groups assigned to Vit D, Vit C and multivitamin arms (N = 60) tested at baseline on cognitive function and post-intervention. The TBI study will recruit three groups of individuals with post-acute traumatic brain injuries and measure whether there is improved cognitive outcomes (measured by test-retest on a cognitive battery) associated with the supplements shown to be most effective in the pilot study.